“Tranquilizer” is a word that belongs to a particular era of American medicine. It peaked in the 1950s and 1960s, when drugs like meprobamate (Miltown) and chlordiazepoxide (Librium) were prescribed at extraordinary rates and advertised directly to physicians as solutions to the anxieties of modern life. The term has largely disappeared from clinical use, replaced by more precise pharmacological categories. But it persists in public conversation — and more importantly, the drugs it once described are still widely prescribed, widely misused and responsible for a significant share of the country’s addiction and overdose burden.
This article explains what “tranquilizer” means, what drugs fall under that umbrella today, how clinical attitudes toward these medications have shifted over the past 70 years and what the signs of dependence and addiction look like.
What “Tranquilizer” Actually Means
In its broadest historical usage, “tranquilizer” referred to any drug that produced calm, reduced anxiety or sedated the central nervous system without inducing sleep at therapeutic doses. The term was divided into two tiers. “Major tranquilizers” referred to antipsychotic medications — drugs like chlorpromazine (Thorazine) used to treat schizophrenia and other serious psychiatric disorders. “Minor tranquilizers” referred to anxiolytics and sedatives used for anxiety, tension and insomnia in the general population.
When people use the word “tranquilizer” today — in conversation, internet searches or older literature — they’re almost always referring to what was once called minor tranquilizers. This guide uses the term in that sense: drugs prescribed primarily for anxiety and sleep that act on the central nervous system by enhancing or mimicking inhibitory signaling in the brain.
Clinicians no longer use “tranquilizer” as a drug classification. The drugs in question are now categorized as benzodiazepines, non-benzodiazepine sedative-hypnotics (Z-drugs), barbiturates or other CNS depressants, depending on their mechanism of action. But the functional category remains intact: These are drugs that slow the central nervous system, reduce anxiety and carry significant potential for dependence.
A Brief History: From Miltown to the Benzo Era
The tranquilizer era began in earnest in 1955, when meprobamate was introduced to the U.S. market under the brand name Miltown. It was the first drug explicitly marketed as a treatment for everyday anxiety rather than serious psychiatric illness, and its commercial success was immediate. By 1957, meprobamate was the best-selling prescription drug in the United States. It was prescribed to housewives, executives and anyone a physician deemed overstimulated by modern life. The term “tranquilizer” entered mainstream vocabulary as a synonym for a new category of pharmaceutical comfort.
Meprobamate was a barbiturate-adjacent compound with a narrow therapeutic index, meaning the difference between a therapeutic dose and a dangerous one was uncomfortably small. As its dependence liability became apparent through the late 1950s and into the 1960s, the pharmaceutical industry moved toward a new class of molecules: benzodiazepines.
Chlordiazepoxide (Librium) was approved in 1960, followed by diazepam (Valium) in 1963. Valium became what Miltown had been — the defining prescription of its decade — and then exceeded it. By 1978, diazepam was the most prescribed drug in the world. The Rolling Stones captured the cultural moment in their 1966 song “Mother’s Little Helper,” a portrait of suburban dependence on the little yellow pill. Benzodiazepines were considered a safer alternative to barbiturates, and in one narrow sense they were: They were less acutely lethal in overdose. But their dependence liability proved substantial, a fact that took decades to fully enter clinical consensus.
Through the 1980s and 1990s, regulatory scrutiny of benzodiazepines increased, prescribing guidelines tightened and the drugs fell somewhat out of favor as first-line anxiety treatments. Selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) — drugs with better long-term safety profiles and no significant dependence liability — became the preferred pharmacological treatment for anxiety disorders. Benzodiazepines were repositioned as short-term adjuncts rather than maintenance therapy.
That repositioning was only partially successful. Benzodiazepine prescribing rates remained high through the 2000s and 2010s, and the drugs became an increasingly significant component of the opioid overdose crisis — not as the primary driver, but as a dangerous co-factor. The CDC reported that benzodiazepines were involved in approximately 16% of opioid overdose deaths in 2019, a figure that reflects the lethal synergy between opioid-induced and benzodiazepine-induced respiratory depression.
What Falls Under This Category Today
The drugs that would have been called tranquilizers in 1965 now occupy several distinct pharmacological categories. The following covers the major classes.
Benzodiazepines
Benzodiazepines are the dominant class of drugs in this category and the most clinically significant from an addiction standpoint. They work by enhancing the effect of gamma-aminobutyric acid (GABA), the brain’s primary inhibitory neurotransmitter, at the GABA-A receptor. The result is anxiolytic, sedative, anticonvulsant and muscle-relaxant effects, depending on dose.
Commonly prescribed benzodiazepines include diazepam (Valium), alprazolam (Xanax), clonazepam (Klonopin), lorazepam (Ativan) and temazepam (Restoril). They vary primarily in potency and half-life — how long they remain active in the body. Short-acting, high-potency benzodiazepines like alprazolam carry a higher addiction liability than longer-acting compounds like diazepam, in part because their rapid onset and offset produces a more reinforcing pharmacokinetic profile.
Current clinical guidelines from organizations including the American Psychiatric Association recommend benzodiazepines for short-term use only — generally 2 to 4 weeks — for anxiety and insomnia, with longer use reserved for specific conditions such as seizure disorders or alcohol withdrawal management. Long-term prescribing for anxiety remains common in practice despite these guidelines.
Z-Drugs (Non-Benzodiazepine Sedative-Hypnotics)
Z-drugs — so named because the three original compounds all begin with the letter Z — include zolpidem (Ambien), zaleplon (Sonata) and eszopiclone (Lunesta). They were developed in the 1980s and 1990s as alternatives to benzodiazepines for insomnia, with the premise that their more selective receptor binding would produce fewer side effects and less dependence risk.
That premise has proven partially correct. Z-drugs are generally less likely to produce physiological dependence than benzodiazepines at therapeutic doses, though dependence does occur. They’re associated with a distinctive set of side effects — including complex sleep behaviors such as sleepwalking, sleep-driving and sleep-eating — that led the FDA to issue a black box warning for zolpidem in 2019. Like benzodiazepines, they’re recommended for short-term use only.
Barbiturates
Barbiturates were the pharmacological predecessors to benzodiazepines and represent an older, less selective class of CNS depressants. They include phenobarbital, secobarbital (Seconal) and butalbital. Their medical use has declined sharply since the 1970s due to their narrow therapeutic index — fatal overdose is possible at doses only modestly above the therapeutic range — and their high dependence liability.
Phenobarbital retains a clinical role in seizure management and is still used in some protocols for alcohol and benzodiazepine withdrawal. Butalbital remains present in combination headache medications. But barbiturates as a drug class no longer occupy a significant place in outpatient psychiatry or primary care prescribing.
Buspirone
Buspirone (Buspar) occupies an unusual position in this category. It’s prescribed for generalized anxiety disorder and often grouped with anxiolytics in clinical discussion, but its mechanism is entirely different from benzodiazepines — it acts on serotonin and dopamine receptors rather than GABA. Critically, it doesn’t produce sedation, doesn’t carry dependence liability and has no significant abuse potential. It’s included here because it’s frequently prescribed in contexts where benzodiazepines once would have been the default and because patients sometimes conflate it with drugs in the tranquilizer class.
Carisoprodol (Soma)
Carisoprodol is a muscle relaxant that’s metabolized in the body to meprobamate — the original Miltown. It is prescribed for acute musculoskeletal pain and carries significant misuse potential, particularly in combination with opioids. The DEA classified it as a Schedule IV controlled substance in 2012. It represents a direct pharmacological link between the tranquilizer era of the 1950s and contemporary patterns of CNS depressant misuse.
Risks: Dependence, Withdrawal and Overdose
Physical Dependence
Physical dependence on benzodiazepines and related drugs can develop within weeks of daily use at therapeutic doses, a timeline many patients and prescribers underestimate. The brain adapts to the chronic presence of a GABA-enhancing drug by downregulating GABA receptor sensitivity, meaning the nervous system becomes calibrated to the drug’s presence. When the drug is removed or reduced, the inhibitory tone that was artificially enhanced disappears and the excitatory systems of the brain — now relatively unopposed — produce a withdrawal syndrome.
Withdrawal
Benzodiazepine and barbiturate withdrawal is medically serious and, in severe cases, life-threatening. It shares its mechanism and risk profile with alcohol withdrawal: Both involve rebound hyperexcitability of a nervous system that’s been chronically suppressed. Withdrawal symptoms include severe anxiety, insomnia, tremor, sweating, hypertension, rapid heartbeat and in serious cases, seizures and delirium.
The timeline of withdrawal varies significantly by the half-life of the specific drug. Short-acting benzodiazepines like alprazolam produce withdrawal symptoms within 12 to 24 hours of the last dose; long-acting compounds like diazepam may not produce significant symptoms for several days. Protracted withdrawal syndrome — a prolonged low-grade syndrome of anxiety, insomnia and cognitive difficulty — can persist for months after acute withdrawal resolves, particularly in long-term users.
Benzodiazepine withdrawal should never be managed through abrupt discontinuation without medical supervision. The standard clinical approach is a gradual taper, often using a long-acting benzodiazepine as a substitution agent, over a period of weeks to months depending on the severity of dependence.
Overdose
Benzodiazepines alone, in overdose, are rarely fatal in otherwise healthy individuals. The primary overdose risk is respiratory depression — the slowing of breathing to dangerous levels — which becomes acutely dangerous when benzodiazepines are combined with other CNS depressants, particularly opioids or alcohol. This combination lethality is the central reason benzodiazepines have become a prominent feature of the opioid overdose crisis. Flumazenil, a benzodiazepine receptor antagonist, can reverse benzodiazepine sedation but is used cautiously in clinical settings due to the risk of precipitating acute withdrawal in dependent patients.
Signs That Use Has Become a Problem
The line between therapeutic use and problematic use of CNS depressants isn’t always clear, particularly for patients who’ve been on long-term prescriptions. Several patterns indicate that use has moved beyond therapeutic:
- Tolerance — needing more of the drug to achieve the same effect — is an early indicator of physiological adaptation. Using more than prescribed, obtaining prescriptions from multiple providers or using someone else’s prescription all indicate a loss of control over use. Continued use despite negative consequences — cognitive impairment, falls, relationship problems, employment difficulties — reflects the compulsive quality of addiction.
- Anxiety or insomnia that appears to worsen over time despite continued medication use is a clinically important sign. This pattern, sometimes called rebound anxiety, reflects the brain’s adaptation to the drug and often leads patients and prescribers to increase dosage rather than taper, a cycle that deepens dependence.
- Preoccupation with the next dose, anxiety about running out and organizing daily life around medication availability are behavioral markers consistent with substance use disorder, regardless of whether the drug was originally obtained by prescription.
When to Seek Help
Anyone who’s concerned about their use of benzodiazepines or related medications should consult a physician before making any changes to their dosage. The specific danger of this drug class — that abrupt discontinuation can cause seizures — makes self-managed tapering genuinely risky. Medical supervision isn’t optional; it’s a clinical necessity.
For people whose use has escalated to the point of addiction — compulsive use despite consequences, inability to reduce despite wanting to, withdrawal symptoms between doses — formal addiction treatment is appropriate. Medical detox provides supervised withdrawal management, typically using a slow taper protocol. Residential or outpatient treatment addresses the behavioral and psychological dimensions that maintain the addiction beyond the physical dependence.
The presence of co-occurring opioid use significantly raises the medical urgency. Combined CNS depressant dependence requires careful clinical management and should be treated at a facility with experience in complex polysubstance withdrawal.
The National Rehab Hotline can help identify treatment programs with appropriate expertise in benzodiazepine and CNS depressant addiction, verify insurance coverage and assist with the logistics of entering care. The service is free and available 24 hours a day.
